US Stock MarketDetailed Quotes

PSTV Plus Therapeutics

Watchlist
  • 1.4450
  • +0.0150+1.05%
Close Aug 23 16:00 ET
8.52MMarket Cap-467P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Stock Region
    Stock Region
    Aug 13 11:52
    Clinical-stage Therapeutics Company Presents Positive Clinical Trial Results
    Plus Therapeutics Announces Encouraging Clinical Trial Outcomes at the 2024 SNO/ASCO CNS Metastases Conference.
    Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, recently presented promising data from their ReSPECT-LM clinical trial at the 2024 Society for Neuro-Oncology (SNO) and American Society for Clinical Oncology (ASCO) CNS Metastases Conference. The trial focuses on evaluating the sa...
    Jaguar8
    Jaguar8
    Aug 13 08:22
    NEWS
    $Plus Therapeutics (PSTV.US)$
    Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
    Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
    CNSide in...
    Trytosaveabit
    Trytosaveabit
    Aug 12 06:34
    Update
    $Plus Therapeutics (PSTV.US)$ Benzinga· 1 min ago
    Plus Therapeutics Presented Data In Podium Presentation Updating The Progress Of Its ReSPECT-LM Trial Of Rhenium Obisbemeda In Leptomeningeal Disease At The 2024 Society For NeuroOncology/American Society For Clinical Oncology CNS Metastases Conference
    1
    Trytosaveabit
    Trytosaveabit
    Jun 7 07:53
    Hmm
    $Plus Therapeutics (PSTV.US)$ Plus Therapeutics (PSTV) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded in September 2022.
    The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.
    1
    Trytosaveabit
    Trytosaveabit
    May 15 15:37
    $Plus Therapeutics (PSTV.US)$ Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last ye...
    2
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg